Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of YY001 in Advanced Solid Tumors
NCT06228846Phase 1Completed
- Sponsor
- Yuyao Biotech
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YY001 in solid tumor (advanced stage), sponsored by Yuyao Biotech. Primary endpoints: Dose limiting toxicity at 24 days, Maximum tolerated dose at 24 days and 1 more. Started Jul 2022; status: completed.
02
Drugs
YY001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06228846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228846.